The study concluded that when dogs were administered ilunocitinib for 56 days at 1X or 3X the labeled dose, the number of dogs with protective titers on days 43 and 56 following administration of canine core booster vaccinations, including rabies, were similar among all treated and control groups. No serious adverse events were observed.